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Abstract
Background: An important mechanism of endocrine activity is chemicals entering target cells via transport
proteins and then interacting with hormone receptors such as the estrogen receptor (ER). a-Fetoprotein (AFP) is a
major transport protein in rodent serum that can bind and sequester estrogens, thus preventing entry to the
target cell and where they could otherwise induce ER-mediated endocrine activity. Recently, we reported rat AFP
binding affinities for a large set of structurally diverse chemicals, including 53 binders and 72 non-binders.
However, the lack of three-dimensional (3D) structures of rat AFP hinders further understanding of the structural
dependence for binding. Therefore, a 3D structure of rat AFP was built using homology modeling in order to
elucidate rat AFP-ligand binding modes through docking analyses and molecular dynamics (MD) simulations.
Methods: Homology modeling was first applied to build a 3D structure of rat AFP. Molecular docking and
Molecular Mechanics-Generalized Born Surface Area (MM-GBSA) scoring were then used to examine potential rat
AFP ligand binding modes. MD simulations and free energy calculations were performed to refine models of
binding modes.
Results: A rat AFP tertiary structure was first obtained using homology modeling and MD simulations. The rat AFP-
ligand binding modes of 13 structurally diverse, representative binders were calculated using molecular docking,
(MM-GBSA) ranking and MD simulations. The key residues for rat AFP-ligand binding were postulated through
analyzing the binding modes.
Conclusion: The optimized 3D rat AFP structure and associated ligand binding modes shed light on rat AFP-ligand
binding interactions that, in turn, provide a means to estimate binding affinity of unknown chemicals. Our results
will assist in the evaluation of the endocrine disruption potential of chemicals.
Background
The potential for environmental and exogenous chemicals
to interfere with hormone (endocrine) systems in both
humans and wildlife has been an international scientific
debate that has persisted for many decades [1]. Concerns
associated with so-called endocrine disruptors (EDs) led to
requirements in the Food Quality Protection Act of 1996
(FQPA1996) and the Safe Drinking Water Act Amend-
ments of 1996 (SDWA Amendments 1996) for the
Environmental Protection Agency (EPA) to screen and
identify substances with hormonal effects. In accordance
to these acts, the EPA developed the Endocrine Disruptor
Screening Program (EDSP) to identify chemicals with
potential for endocrine disruption [2]. The endocrine
system comprises glands that produce hormones and the
receptors that respond to those hormones [3], as well as
other proteins that can bind the hormones in serum [4].
EDs can mimic endogenous hormone ligands acting
as agonists, partial agonists, or antagonists, altering gene
* Correspondence: huixiao.hong@fda.hhs.gov
1Division of Bioinformatics and Biostatistics, National Center for Toxicological
Research, U.S. Food and Drug Administration, 3900 NCTR Road, Jefferson, AR
72079, USA
Full list of author information is available at the end of the article
Shen et al. BMC Bioinformatics 2013, 14(Suppl 14):S6
http://www.biomedcentral.com/1471-2105/14/S14/S6
© 2013 Shen et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
expression and homeostasis, resulting in adverse develop-
mental, reproductive, neurological and immune system
effects [5]. The ability of chemicals to bind hormone
receptors is a major mechanism for altering endocrine
activity. Exogenous chemical binding to ER is particularly
concerning due to potential for altering normal estrogen
signaling through genomic and non-genomic pathways
[6-8].
AFP is a serum protein in mammals that is produced in
the yolk sac and liver of a developing fetus [9]. It is a
member of the albuminoid gene superfamily. In human,
AFP has long been used as a serum marker for fetal
defects and tumor progression [10]. In rodents, AFP
sequesters endogenous estrogen [11], blocking entry
where it would otherwise induce ER-mediated responses.
To better estimate ER binding potential of a chemical in
rodents, it is important to know its rat AFP binding
properties. In 1972, Uriel et al. first reported the binding
properties of rat AFP to steroidal chemicals using an
immuno-autoradiographic assay [12]. Thereafter, rat AFP
has been used to study in vitro binding and in vivo trans-
port of steroids [13-15]. Recently, we developed a competi-
tive binding assay using rat amniotic fluid, and used it to
measure AFP binding affinities to 125 chemicals in 15
diverse, structural categories [4]. Some 53 chemicals from
13 categories bound AFP, while 72 chemicals did not.
Importantly, we previously also measured ER binding
affinity for 114 of the 125 chemicals, of which 47 bound
both ER and AFP, 42 bound only ER, and 19 bound
neither AFP nor ER. ER binding was not measured for the
remaining 11 chemicals. These data provide a large dataset
to study ligand to rat AFP binding preferences. Two possi-
ble estrogen-binding sites on rodent AFP have been pro-
posed based on experimental binding data [16,17];
however, no 3D structures for rat AFP (with or without
bound ligands) were available to confirm the binding site-
sand structural dependencies on site activity.
Computational methods to predict protein structure
and ligand-protein interaction have been successfully
applied in biochemical research for decades. Terentiev
et al. have reported the 3D homology model of human
AFP in 2012[18]. In their work, the 3D model of human
AFP was built to study the interaction of human AFP
and diethylstilbestrol (DES), which is a strong ER binder
and a validated endocrine disruptor. Herein, we built a
3D structure for rat AFP using homology modeling with
subsequent optimization with MD simulations. Using
the optimized 3D rat AFP structure, the rat AFP-ligand
binding modes for 13structurally diverse rat AFP
binders were calculated with molecular docking,
followed by refinement using MD simulations.
This study reports the first 3D structure of rat AFP that
was built through homology modeling and optimized
using MD simulations. The 3D structure was
demonstrated to be stable and trustworthy. Based on the
3D structure, the ligand binding modes of 13 structural
diverse rat AFP binders were elucidated using molecular
docking. Moreover, rat AFP conformation changes
induced by ligands during the MD simulations were
observed. Ligand binding free energies of the rat AFP
binders were calculated using the MM-GBSA method and
revealed that rat AFP can accommodate structurally
diverse ligands having different electrostatic and hydro-
phobic properties. Glu206 was found to be the most
important residue for rat AFP binding to flavones and
mycoestrogens, while Tyr168 was most important for
binding benzophenones and coumarin.
Materials and methods
Study design
The study design and workflow are depicted in Figure 1.
Briefly, the rat AFP protein sequence was first searched
in the protein data bank (PDB) using BLAST to select a
template protein highly homologous to rat AFP. An
initial 3D rat AFP structure was then built using homol-
ogy modeling. The 3D structure was subsequently opti-
mized with MD simulation. The optimized 3D rat AFP
structure was used to define a binding grid for docking
analyses. Thirteen structurally diverse rat AFP binders
were selected from our previously reported results[4]
and their 3D structures were built and optimized. The
optimized 3D structures of the 13 rat AFP binders were
then docked into the docking grid. The rat AFP-ligand
complexes from docking analyses were further
optimized through MD simulations. Finally, the rat
AFP-ligand binding mode and the ligand binding free
energy for each AFP binder were analyzed based on the
trajectories of MD simulations.
Homology modeling
The sequence of rat AFP was downloaded from the
universal protein resource (Uniprot) [19] (entry: P02773).
The template for sequence alignment was identified
through searching rat AFP on PDB using the BLASTp
[20] program provided by Uniprot with default para-
meters. The 3D structure of rabbit serum albumin (Uni-
prot ID: G1U9S2) was downloaded from PDB (PDB ID:
4V5F) [21] as the template structure. The homology
model of rat AFP was built with Prime 3.1 in Schrödinger
Suite (Schrödinger, LLC, New York, NY). The secondary
structure of rat AFP was predicted using the SSpro
program bundled with Prime. The target (rat AFP) and
template (rabbit serum albumin) sequences were aligned
using the ClustralW method employed in Prime,
followed by manual adjustment to avoid big gaps in the
secondary structure domain. The original ligand in the
template structure was removed before homology
modeling.
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MD optimization
The initial 3D structure of rat AFP obtained from homol-
ogy modeling was optimized using MD simulation. The
Amber ff03.R1 [22] force field was applied to the protein.
Topology and parameter files were generated using the
LEaP program[23]. MD simulation was conducted using
Amber11 [23]. The 3D rat AFP structure was surrounded
by a truncated octahedron periodic box of TIP3Pwater
molecules with a margin of 10.0 Å along each dimension.
Sodium ions were added to the system to maintain its
charge neutrality. All covalent bonds to hydrogen atoms
were constrained using the SHAKE algorithm[24]. Electro-
static interactions were calculated using the particle-mesh
Ewald (PME) algorithm [25]with a cutoff of 10 Å for Len-
nard-Jones interactions. Periodic boundary conditions
were applied to avoid edge effects. Prior to MD produc-
tion, 500 steps of steepest-descent minimization and 1500
steps of conjugated gradient minimization were applied to
the solvent and the entire model system, respectively. The
entire system was heated from 0 to 300 K gradually over
30 ps (picoseconds) using the NVT (constant volume and
normal temperature) ensemble with the solutes restrained
by a weak harmonic potential. During the heating, time
constant for heat bath coupling for the solute was set as
1.0.Afterward, 140 ps of equilibrations were carried out in
the NPT (constant normal pressure and normal tempera-
ture) ensemble via three steps: first the solutes were
restrained while the waters and counter-ions were
equilibrated in the first 20 ps; then the side chains of rat
AFP were relaxed in the next 20 ps; last, all the restraints
were removed in the last 100 ps. Finally, 10 ns (nanose-
conds) MD simulations were conducted at 1 atm and 300
K under the NPT ensemble with a time step of 2 fs
(femtoseconds). The temperature was controlled using
Langevin dynamics. The coordinates of all atoms in the
system were saved every 1 ps during the entire MD
simulations.
Ligand preparation
Our previous study [4] identified 53 rat AFP binders from
13 structural categories. The most potent binder in each
category was selected as the exemplars for docking
analyses. The structures and chemical names are given in
Figure 2. The 3D structures for these were built using
Ligprep2.5 in Schrödinger Suite with an OPLS_2005 force
field. Their ionization states were generated at pH7.0±2.0
Figure 1 Study design and overall workflow. BLAST was used for the rat AFP protein sequence against PDB to select a template sequence
for homology modeling. The initial 3D structure obtained from homology modeling was further optimized using MD simulation. The optimized
3D structure was used as the docking receptor. Thirteen structurally diverse rat-AFP binders were selected from our recently reported results [4]
and were docked into the receptor. Finally, the ligand binding free energy for the complex was calculated based on the MD simulations.
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using Epik2.2 in Schrödinger Suite. Up to 32 possible
stereoisomers per ligand were retained.
Docking grid generation
Prior to molecular docking, the optimized 3D rat AFP
structure was prepared using the “Protein Preparation
Wizard” workflow in Schrödinger Suite. Bond orders were
assigned and hydrogen atoms were added to the protein.
The structure was then minimized to reach the converged
root mean square deviation (RMSD) of 0.30 Å with the
OPLS_2005 force field. Probable ligand binding sites (on
or near the protein surface) were searched using
SiteMap2.6 in Schrödinger Suite. Then, contour maps of
hydrophobic and hydrophilic fields were generated. The
hydrophilic maps were further divided into donor, accep-
tor, and metal-binding regions. Finally, all the sites were
assessed by calculating various properties. Thereafter, a
docking grid was defined using “Receptor Grid Genera-
tion” in Schrödinger Suite. The grid enclosing box was
centered in rat AFP with an internal size of 14 × 14 × 14
(x × y × z, Å). The grid was made large enough to cover
all the potential ligand binding sites in the protein. Since
the active site of rat AFP is not tight and encapsulated, the
scaling factor of Van der Waals radius was set as 1.0 with
a partial atomic charge less than 0.15 e, which means no
scaling is done in this case.
Molecular docking
The optimized 3D structures of the 13 rat AFP binders
were docked into the docking grid in the 3D structure
of rat AFP using Glide5.8 in Schrödinger Suite with
standard precision (SP). The final binding poses with
the top glide score were selected for further optimiza-
tion through MD simulations.
MD simulations
MD simulations were performed for the 13 rat AFP-ligand
complexes using the similar protocol described in the MD
optimization section. The ligands were optimized at the
Hartree-Fock level with the 6-31G(d,p) basis set using
Gaussian 09 (Gaussian, Inc., Wallingford, CT). Restrained
electrostatic potential (RESP) charges were then calculated
using the B3LYP/cc-pVTZ quantum mechanical method.
The general Amber force field (GAFF) was applied to the
complexes [26]. Topology and parameter files were
generated using the LEaP program [24].The force field
Figure 2 Chemical structures and names of the 13 representative rat-AFP binders used in this study.
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parameters of ligands wereobtained from the Antecham-
ber modulein the AmberTools1.5 program [24]. The
system minimization, heating, and equilibration were
carried out in the same manner used for the optimization
of 3D rat AFP structure described above. The MD simula-
tions were performed for up to 60 ns for each complex
system. The coordinates of atoms in the complex were
saved every 10ps during the simulations.
Binding free energy calculation
The binding free energy (ΔGbinding, equation (1)) for
each rat AFP-ligand complex system was calculated
using the MM-GBSA approach [27]. A total of 1000
snapshots were taken in atime slice of 50-60 ns MD
simulation trajectory to calculate the MM-GBSA free
energy difference. For each snapshot, the rat AFP-ligand
binding free energy was calculated using equation (1).
Gbinding = Gcomplex − (Gprotein + Gligand) (1)
where Gcomplex, Gprotein and Gligand are free energies of
complex, protein and ligand, respectively. Each of the
components was estimated using equation (2),
G = Ggas +Gsolv − TS (2)
where ΔGgas is the molecular mechanics free energy in
gas phase, including electrostatic and van der Waals
contributions (equation (3)). ΔGsolv is the solvation free
energy, including polar (ΔGGB) and nonpolar (ΔGSA)
contributions (equation (4)).
Ggas = Eelectrostatic +Evdw (3)
Gsolv = GGB +GSA (4)
GSA = γ × SASA + b (5)
The polar contribution (ΔGGB) was calculated with the
modified GB model described by Onufriev et al. [28]
using εw= 80 and εp=1.0. SASA is the solvent-accessible
area that is determined using the linear combination of
pairwise overlaps method [29]. The surface tension pro-
portionality constant g and the free energy of nonpolar
solvation for a point solute b were set to 0.0072 kcal/
mol/Å2 and 0.00 kcal/mol, respectively. The radius of
the probe sphere used to calculate SASA was set to 1.4
Å. The entropy calculation is only a rough estimation
with normal mode analysis. The calculated free energies
were used for comparisons among the 13 rat AFP bin-
ders. Therefore, the entropy term was not included in
our analyses. The final binding free energy for a rat AFP
binder was the average value from the 1000 snapshots
in the last 10 ns of MD simulations.
Results and discussions
Optimized 3D structure of rat AFP
With an identity of 34% and an alignment score of 1079,
the sequence of rabbit serum albumin (Uniprot ID:
G1U9S2) has the highest ranked homology in the
BLAST search for rat AFP on proteins in PDB. Recent
studies have demonstrated that 3D structures are similar
if the sequence identity between two proteins is higher
than 25% [30,31]. Therefore, the 3D structure of rat
AFP built through homology modeling using the 3D
structure of rabbit serum albumin as the template
should be suitable for modeling rat protein binding
data. The crystal structure of rabbit serum albumin was
recently determined at a resolution of 2.27Å [21] and
was deposited in PDB (PDB ID: 4V5F). The amino acid
sequence of the rabbit serum albumin crystal structure
is from Glu25 to Gly608 and covers the full length of
rat AFP except for the 24 amino acids in the N termi-
nus (Figure 3).
The initial alignment of rat AFP sequence with the tem-
plate sequence was obtained using ClustalW. The align-
ment is consistent with experimental results [32] reporting
that 15 disulphide bridges in the template structure are
perfectly aligned to the rat AFP sequence (see Figure 3,
where cystines are highlighted in yellow). The region of
residues 70-110 in rat AFP could not be aligned with the
template because rat AFP is larger. This region was
manually adjusted according to the predicted secondary
structures of rat AFP to avoid large gaps located inside the
secondary structures of the template. The final alignment
(32% identity, 51% positivity, and 4% gaps) used in the
homology modeling and in the secondary structure predic-
tion is shown in Figure 3. Besides the disulphide bridges,
most of the secondary structures align well between the
template and rat AFP. The initial homology models of rat
AFP were built using Prime, with the model with the
lowest energy used for further optimization.
MD simulation has been commonly applied to refine
homology models [33]. Herein, the initial 3D structure of
rat AFP from homology modeling was optimized using
MD simulation in solvent to mimic the real physiological
environment. The stability of rat AFP structure during the
MD simulation was measured by its deviation from the
initial structure in terms of RMSD. The RMSD values of
the rat AFP backbone atoms and all atoms in the entire
MD simulation trajectory were as shown in Figure 4a. The
3D structures of rat AFP reached a stable state after 6 ns
where the RMSD of the protein backbone atoms and of all
atoms converged to 4 Å and 4.5Å, respectively. The root-
mean-square fluctuations (RMSF) of all rat AFP structures
generated during the MD simulation were calculated to
characterize the mobility of individual residues as shown
in Figure 4b. The side chain residues from 70 to 90 had
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high peaks in the RMSF plot (Figure 4b), indicating large
fluctuations of those residues. Examining this region in
the structures generated during the MD optimization
revealed that the loop in the initial rat AFP structure
folded into a small helix after the MD simulations (Figure
4c). The Ramachandran plot (Supplementary Figure S1 in
additional file 1) of the optimized rat AFP structure
showed that 99.3% of residues were placed in allowed
regions, higher than the percentage of residues (98.6%) in
allowed regions for the initial 3D rat AFP structure from
homology modeling, indicating higher stability of the
optimized rat AFP structure. The residues located in the
favored zone were also increased from 91.1% to 92.5%
after MD optimization. As a reference, the template crystal
structure of rabbit serum albumin only had 92.2% and
99.0% residues in the favored and allowed zones, respec-
tively. This indicates that the optimized rat AFP structure
should be stable and reliable for use in elucidating of rat
AFP-ligand binding modes through molecular docking
and MD simulations.
Binding modes generated by molecular docking
The two putative rat AFP binding sites proposed without
the benefit of crystal structure data were speculative
[16,17]. Herein, we used SiteMap [34] to search and ana-
lyze the potential ligand binding sites in rat AFP. To
elucidate possible binding modes of different ligands, a
large box was defined to cover all the potential binding
sites generated by SiteMap. Therefore, the 13 ligands
adopted the most favorable binding poses.
Different binding poses of the 13 ligands were
searched and ranked by docking analysis based on their
docking scores. The pose with the lowest score, suggest-
ing the most probable binding modes of a ligand, was
selected for further analysis. The 13 rat AFP binders
were successfully docked in a big pocket inside rat AFP.
The preferable ligand binding poses for the 13 rat AFP
binders are depicted in supplementary Figure S2 in
additional. Twelve binders were docked in the site
composed of residues Glu206, Glu209, Gly210, Leu213,
Lys236, His260, Try306, and His310. The orientations of
all 12 binders are similar: the hydrophobic part of the
binders extends into the binding pocket, while the
hydroxyl group-tethered part extends out to form
hydrogen bonds with AFP (Figure 5a). Only one binder,
DL-hexestrol, bound to the opposite site composed of
Leu233, Gln239 and Glu312, in the same pocket. Two
hydrogen bonds were formed between the two hydroxyl
groups of DL-hexestrol and the ketone group of the
Gln239 and Leu233 backbone. As shown in Figure 5b,
DL-hexestrol folded in the binding site in the conforma-
tion that is not energy-favorable. The energy
Figure 3 Sequence alignment result between rat AFP and the template sequence of rabbit serum albumin. The predicted secondary
structure of rat AFP is also shown, where E represents for strand; H for helix; and - for loop. The identical residues are highlighted in colors
according to the property of the corresponding query residue in the alignment to depict the location of charged, polar, and hydrophobic query
residues.
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unfavorable binding mode might explain the weak
binding affinity observed for DL-hexestrol.
The binding poses of the 13 rat AFP binders were
assessed using the GScore scoring function comprised
van der Waals energy, Coulomb energy, hydrophobic
interactions, hydrogen bonding, polar interactions, and
rotatable bonds penalty. The docking scores of the 13
rat AFP binders as well as their experimentally- deter-
mined binding affinities (IC50) are given in supplemen-
tary Figure S2. Quercetin had the lowest docking score.
The docking results revealed that a hydrogen bonding
network formed between the hydroxyl groups in the
dihydroxybenzene part of quercetin and the residues
Glu206, Tyr306 (supplementary Figure S2 in additional
Figure 4 MD profiles of the rat AFP tertiary structure optimization. a) RMSD values (y-axis) along the time frame (x-axis) for atoms of
protein backbone (black line) and ligand binding pocket (red line); b) RMSF values (y-axis) in MD simulation for individual along residues (x-axis);
c) The loop from residues 70-90 folded to the helix after MD simulations (gray: initial models; yellow: after 5 ns MD simulation; green: after 10 ns
MD simulation).
Figure 5 Docking poses of the 13 rat AFP binders. Binders are represented by constant colored sticks and protein are represented by lines
and colored according atom types. The binding pocket surface is colored by electrostatic properties. a) Most ligands bind to the pocket
comprising Glu206, Glu209, Gly210, Leu213, Lys236, His260, Try306, and His310; b) one ligand binds to the pocket composed of Leu236, Gln239
Tyr306, Ile309, His310, Glu312, Asn313, Leu359, Val361, Ala465 and Ile473.
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file 1). Such a hydrogen bonding network is likewise
observed in the docking poses of coumestrol, a-zearala-
nol, diethylstilbestrol (DES), dioxybenzone, and heptyl
p-hydroxybenzoate (supplementary Figure S2 in addi-
tional file 1). Estrone and 2,3,4,5-tetrachloro-4’-bipheny-
lol were the two most potent rat AFP binders, and were
also highest ranked in the docking analyses. Further
examination of the bind poses indicated major contribu-
tions to their affinity are hydrophobic interactions.
Binding modes refined by MD simulations
While molecular docking has been successfully used in
predicting binding poses of ligands for many proteins, it
has also failed in estimating of ligand binding affinity
[35,36]. One of the major reasons for failure is treatment
of proteins as “rigid” molecules in order to save computa-
tional time, and thus not allowing their conformations to
adjust during docking. The rigidity assumption works well
for proteins that lack flexibility. However, AFP is a very
flexible protein, and AFP conformation change induced by
some ligands has been reported [37,38]. MD simulation
has been extensively applied to study conformation
changes in protein-ligand interactions [39,40], protein
dynamics [41,42], and protein folding [43,44]. Given AFP
flexibility, MD simulations were deemed necessary to
compare rat AFP conformation changes anticipated to dif-
fer across the 13 structurally diverse binders.
In this study, MD simulations were carried out on the
13 rat AFP-ligand complex systemsto refine understand-
ing of rat AFP binding modes obtained from molecular
docking. The dynamic stabilities of the 13 complex sys-
tems were estimated using RMSD changes during the
MD simulations as plotted in Figure 6 and supplemen-
tary Figure S3 in additional file 1. For the complexes of
rat AFP bound with estrone, dihydorxymethoxychlorole-
fin, quercetin, coumestrol, heptyl p-hydroxybenzoate,
DL-hexestrol and dioxybenzone, the protein was equili-
brated with no obvious RMSD fluctuations observed
after 20 ns. For the complexes of rat AFP bound with
2,3,4,5-tetrachloro-4’-biphenylol, DES and flavanone,
RMSDs gradually increased in the first 50 ns and then
converged in the time frame from 50 to 60 ns. The
complex of rat AFP bound with a-zearalanol quickly
equilibrated, though large RMSD fluctuations occurred
during the last 5 ns, possibly due to the motions of the
loop around Glu363 to Lys377. This loop is far from the
ligand binding pockets and may thus minimally affect
ligand binding. For the complexes of rat AFP bound
with chalcone and diethyl phthalate (the two weakest rat
AFP binders among the 13), large fluctuations were
observed during the MD simulations (Figure 6d and
supplementary Figure S3 in additional file 1). Interest-
ingly, trajectory analysis revealed that diethyl phthalate
exited the binding pocket after 10 ns, which is hardly
surprising since weak binding affinity was measured for
this binder in our previous study [4]. We also analyzed
stability and conformation change with RMSD during
the MD simulations of the 13 binders. Conformation
changes were observed for all binders (see Figure 6 and
supplementary Figure S3 in additional file 1). Moreover,
binders with multiple rotatable bonds fluctuated more
than rigid binders. For example, diethyl phthalate that
contains two ester chains fluctuated considerably, while
the rigid 2,3,4,5-tetrachloro-4’-biphenylol remained rela-
tively stable during the MD simulations. Interestingly,
binders with high binding affinity were stable even
though they contained multiple rotatable bonds. For
example, although dihydroxymethoxychloroolefin con-
tains a rotatable n-heptane chain, its RMSD remained
near 1 Å throughout the MD simulations. Estrone was
stable during the MD simulation except for the time
frame from 45 to 55 ns when it repositioned to another
binding site in rat AFP, before shifting back after 55 ns.
Because the binding pocket of rat AFP has more volume
than some binders, such as coumestrol and flavanone,
binders can reposition to different binding sites, exhibit-
ing large fluctuations in RMSDs.
Ligand induced conformation changes were observed in
our MD simulations. The superimposition of three bound
complexes from the final snapshots of the MD simulations
shown in Figure 7 (estrone: Red; 2,3,4,5-tetrachloro-4’-
biphenylol: Blue; chalcone: Green) illustrates rat AFP con-
formation changes. Different ligands induced different
conformation changes, though the MD simulations started
from the same rat AFP conformation.
Diethyl phthalate was not able to stay in the binding
pocket, exiting AFP 10 ns after the MD simulation. It
was consequently excluded from the binding free energy
calculation. The binding free energies were calculated
for the rest of 12 binders using MM-GBSA methods
based on the MD simulation trajectories from 50 to 60
ns. The overall binding free energy (ΔGMM-GBSA) and all
energy terms from equations (2) through (5) from the
MM-GBSA method are given in Table 1.
To make direct comparisons between experimental bind-
ing affinities, (ΔGexp) was estimated from binding affinity
data using ΔGexp ≈ -RTlnIC50[45] with results listed in
Table 1. The reason we can make such approximation is
that the dissociation constant Kd is proportional to Zreac-
tants/Zproducts, where Z is ensemble partition function.
Consequently, the MM-GBSA binding free energies were
much lower than the binding free energies estimated from
experimental data. Analyzing the components in the
MM-GBSA biding free energies indicated electrostatic
energy to be the major contributor for binders with high
polarity. For example, ΔGelec was -157 kcal/mol for
quercetin that contains 5 hydroxyl groups, while ΔGelec
was 128 kcal/mol for a-zearalanol that contains 3 hydroxyl
Shen et al. BMC Bioinformatics 2013, 14(Suppl 14):S6
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groups. These two ligands have less unfavorable/positive
nonpolar penalties ΔGnp of 36 and 10 kcal/mol,
respectively.
Conclusions
AFP can change the availability of estrogenic chemicals
to enter target cells. Knowledge of the binding affinity
of an estrogenic chemical is important to estimate its
potential endocrine activity. Such ER-mediated activity
can be altered in rat through binding to AFP that
sequesters estrogen in rat in circulating serum. The
tertiary structures of AFP are crucial to understanding
AFP-ligand interactions for evaluating chemical
endocrine activity. Our results on binding interactions
Figure 6 RMSD in MD simulations. RMSD of protein backbones are represented in blue lines, while RMSD of the ligands are depicted in
red lines. a) the rat-AFP complex with estrone; b) the rat-AFP complex with 2,3,4,5-tetrachloro-4’-biphenylol; c) the rat-AFP complex with
DL-hexestrol; d) the rat-AFP complex with chalcone.
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between chemicals and rat AFP would be helpful for
further studies including evaluation of endocrine disrup-
tion potential of chemicals in the human environment,
and designing more efficient drug products that target
ER or compete with AFP sequestration of drugs.
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Figure 7 The final snapshots (60 ns) of three ligand-protein
complexes in the MD simulations (red: the rat-AFP complex
with estrone; blue: 2,3,4,5-Tetrachloro-4’-biphenylol; green: the
rat-AFP complex with chalcone). The proteins are represented
using ribbon with constant color.
Table 1 Calculated Binding Free Energies in Comparison with Available Experimental Data (All in kcal/mola)




estrone -4.697 -33.641 -38.342 16.386 -43.039 -17.255 -21.956 -14.170
2,3,4,5-tetrachloro-4’-biphenylol -10.820 -34.011 -44.831 13.439 -55.651 -20.571 -31.391 -13.499
dihydroxymethoxychlorolefin -16.178 -35.206 -51.385 17.346 -67.563 -17.861 -34.039 -11.400
quercetin -64.532 -28.019 -92.552 64.173 -157.084 36.154 -28.378 -11.299
diethylstilbestrol (DES) -13.686 -38.031 -51.717 20.007 -65.404 -18.024 -31.710 -11.255
a-zearalanol -44.887 -38.562 -83.449 48.873 -128.336 10.311 -34.576 -10.665
coumestrol -19.018 -39.142 -58.160 23.885 -77.178 -15.257 -34.275 -10.472
heptyl p-hydroxybenzoate -11.911 -30.747 -42.658 19.749 -54.569 -10.998 -22.910 -10.472
DL-hexestrol -8.448 -29.507 -37.952 18.078 -46.400 -11.429 -19.875 -10.256
dioxybenzone -5.791 -35.739 -41.530 17.046 -47.321 -18.694 -24.485 -10.033
flavanone -4.047 -31.029 -35.076 13.354 -39.124 -17.675 -21.722 -9.511
chalcone -15.359 -27.673 -43.033 18.745 -58.392 -8.929 -24.288 -8.766
a Average over 1000 snapshots
b Total electrostatic contribution: ΔGelec= ΔEelectrostatic+ ΔGGB
c Total nonpolar contribution: ΔGnp= ΔEvdw+ ΔGSA
dΔGexpt=RTlnIC50, T = 277K
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